Process for preparing 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-ol (I - enol form) or 2-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one (I - keto form), characterized in that a) in the first step, 1,2,3-triazole is reacted with methyl bromoacetate (IV-Me-Br) or ethyl bromoacetate (IV-Et-Br) in the presence of ethyldiisopropylamine as base in a solvent in the temperature range from 20 to 80°C to form the compounds methyl-1H-1,2,3-triazol-1-yl acetate (V-Me) and methyl-2H-1,2,3-triazol-1-yl acetate (VI-Me) or the compounds ethyl-1H-1,2,3-traizol-1-yl acetate (V-Et) and ethyl-2H-1,2,3-triazol-1-yl acetate (VI-Et), b) in the second step, the compounds methyl-1H-1,2,3-triazol-1-yl acetate (V-Me) and methyl-2H-1,2,3-triazol-1-yl acetate (VI-Me) or the compounds ethyl-1H-1,2,3-traizol-1-yl acetate (V-Et) and ethyl-2H-1,2,3-triazol-1-yl acetate (VI-Et), which are present in a ratio of at least 6:1 to one another, are reacted with dimethylformamide dimethyl acetal (XIX-Me) or dimethylformamide diethyl acetal (XIX-Et) in an inert solvent and are subsequently crystallized by cooling the solution or by distilling off the solvent and adding a second solvent to form methyl (2E/Z)-3-(dimethylamino)-2-(1H-1,2,3-triazol-1-yl)acrylate (VII-Me) or ethyl (2E/Z)-3-(dimethylamino)-2-(1H-1,2,3-triazol-1-yl)acrylate (VII-Et), and c) in the third step, methyl (2E/Z)-3-(dimethylamino)-2-(1H-1,2,3-triazol-1-yl)acrylate (VII-Me) or ethyl (2E/Z)-3-(dimethylamino)-2-(1H-1,2,3-triazol-1-yl)acrylate (VII-Et) is reacted with 4-(6-hydrazinopyrimidin-4-yl)morpholine in the presence of trifluoroacetic acid in an inert solvent and the compound of the formula is subsequently isolated. a) in the first step, 1,2,3-triazole is reacted with methyl bromoacetate (IV-Me-Br) or ethyl bromoacetate (IV-Et-Br) in the presence of ethyldiisopropylamine as base in a solvent in the temperature range from 20 to 80°C to form the compounds methyl-1H-1,2,3-triazol-1-yl acetate (V-Me) and methyl-2H-1,2,3-triazol-1-yl acetate (VI-Me) or the compounds ethyl-1H-1,2,3-traizol-1-yl acetate (V-Et) and ethyl-2H-1,2,3-triazol-1-yl acetate (VI-Et), b) in the second step, the compounds methyl-1H-1,2,3-triazol-1-yl acetate (V-Me) and methyl-2H-1,2,3-triazol-1-yl acetate (VI-Me) or the compounds ethyl-1H-1,2,3-traizol-1-yl acetate (V-Et) and ethyl-2H-1,2,3-triazol-1-yl acetate (VI-Et), which are present in a ratio of at least 6:1 to one another, are reacted with dimethylformamide dimethyl acetal (XIX-Me) or dimethylformamide diethyl acetal (XIX-Et) in an inert solvent and are subsequently crystallized by cooling the solution or by distilling off the solvent and adding a second solvent to form methyl (2E/Z)-3-(dimethylamino)-2-(1H-1,2,3-triazol-1-yl)acrylate (VII-Me) or ethyl (2E/Z)-3-(dimethylamino)-2-(1H-1,2,3-triazol-1-yl)acrylate (VII-Et), c) in the third step, methyl (2E/Z)-3-(dimethylamino)-2-(1H-1,2,3-triazol-1-yl)acrylate (VII-Me) or ethyl (2E/Z)-3-(dimethylamino)-2-(1H-1,2,3-triazol-1-yl)acrylate (VII-Et) is reacted with 4-(6-hydrazinopyrimidin-4-yl)morpholine in the presence of trifluoroacetic acid in an inert solvent and the compound of the formula is subsequently isolated.